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Summary 
CD19deficient mice were generated to examlne the 
role of CD18 in B cell growth regulation in vivo. Dele- 
tion of CD19 had no deleterious effects on the genera- 
tion of 6 cells in the bone marrow, but there was a 
significant reduction in the number of B cells in periph- 
eral lymphoid tissues. B cells from CD19-deficlent 
mice exhibited markedly decreased proliferative re- 
sponses to mitogens, and serum immunoglobulin lev- 
els were also significantly decreased. In contrast, mice 
that overexpressed CD19 had significant defects in 
early B cell development in the bone marrow, aug- 
mented mitogenic responses, and increased serum 
immunoglobulin levels. These experiments indicate 
that CD19 functions to define signaling thresholds for 
cell surface receptors that regulate B lymphocyte se- 
lection, activation, and differentiation. 
Introduction 
B lymphocyte development and maturation into antibody- 
secreting plasma cells is a highly regulated process (Rol- 
ink and Melchers, 1991). A hallmark of B lymphocyte de- 
velopment is the expression of surface immunoglobulin 
receptors, which provide B cells with the ability to respond 
to antigen (Nossal, 1994; von Boehmer, 1994). B cells 
also express other cell surface molecules, which modify 
responses to antigen and are thereby important for B cell 
development, tolerance induction, proliferation, and differ- 
entiation. Among these molecules, CD19 has been pro- 
posed to serve as a coreceptor molecule, important for 
modifying signals generated through the 6 cell antigen 
receptor complex (Cambier et al., 1994; Fearon, 1993; 
Tedder et al., 1994; Weiss and Littman, 1994). In this re- 
gard, the B cell-specific CD1 9 complex shares many func- 
tional properties with the T cell coreceptors CD4 and CD8, 
which function to lower the threshold for cellular activation 
by the T cell antigen receptor (Weiss and Littman, 1994). 
Although little data currently exists to document an in vivo 
function for CD19, signals generated through CD19 can 
amplify or reduce signals generated through the B cell 
antigen receptor complex in vitro and may therefore be a 
critical regulator of 6 cell function (Tedder et al., 1994). 
CD19 is a lineage-specific 95,000 M, glycoprotein ex- 
pressed by early pre-6 cells from the time of immunoglobu- 
lin heavy chain rearrangement until plasma cell differentia- 
tion (Nadler et al., 1983; Tedder and Isaac% 1989; Zhou 
et al., 1991). CD19 is well conserved between humans 
and mice (Tedder and Isaacs, 1989; Zhou et al., 1991, 
1992) and contains two extracellular immunoglobulin-like 
domains and an extensive 240 aa cytoplasmic domain, 
which is necessary for signal transduction activity (Brad- 
bury et al., 1993; Matsumoto et al., 1993). The cytoplasmic 
domain of CD19 associates with the Iyn, Ick, and fyn pro- 
tein tyrosine kinases (Uckun et al., 1993; van Noesel et al., 
1993) and also contains kinase insert regions that when 
phosphotylated mediate the binding and activation of 
phosphatidylinositol3-kinase (Tuveson et al., 1993). CD1 9 
is also a component of a multimeric ceil surface signal 
transduction complex expressed by mature B cells, which 
can include the B cell-restricted CD21 (complement re- 
ceptor type 2 [CR2]) receptor as well as the CD81 and 
Leu-13 molecules that are broadly expressed by other cell 
lineages (Bradbury et al., 1992; Matsumoto et al., 1991). 
It has been proposed that the association between CD1 9 
and CD21 provides a mechanism for bridging the antigen 
receptor complex with the CD1 9 complex through covalent 
complexes of C3d and antigen (Matsumoto et al., 1991; 
van Noesel et al., 1993). 
Ligation of CD19 in vitro initiates a complex series of 
biological responses that may be of central importance to 
B cell signaling, growth regulation, or both (Tedder et al., 
1994). Cross-linking of CD1 9 with monoclonal antibodies 
(MAbs) induces an increase in the intracellular calcium ion 
concentration of 6 cells (Bradbury et al., 1992; Pezzutto 
et al., 1987; Uckun and Ledbetter, 1988) and induces 
tyrosine kinase activity (Carter et al., 1991; Kansas and 
Tedder, 1991). CD1 9 ligation has been reported to provide 
proliferative signals for early IgM-negative precursor B 
cells (Uckun and Ledbetter, 1988) while coligation of 
CD19 with cell surface immunoglobulin lowers the thresh- 
old for B cell proliferation induced by anti-immunoglobulin 
antibodies (Carter and Fearon, 1992; Rigley and Callard, 
1991). However, B cell proliferation and differentiation can 
either be inhibited or enhanced by CD1 9 MAbs depending 
on the mitogenic stimulus used and the degree of cross- 
linking (Barrett et al., 1990; Carter and Fearon, 1992; Pez- 
zutto et al., 1987; Rigley and Callard, 1991). Ligation of 
membrane immunoglobulin can lead to heterologous de- 
sensitization of the signal-transducing ability of CD19 
(Rijkers et al., 1990) suggesting a functional association 
between these receptor complexes. CD1 9 may also physi- 
cally associate with the surface immunoglobulin receptor 
complex under some circumstances, since CD19 can be 
cocapped and internalized with cell surface immunoglobu- 
lin (Bradbury et al., 1992; Pesando et al., 1989). Thereby, 
the CD19 complex may deliver protein tyrosine kinases 
to the B cell antigen receptor complex upon cross-linking. 
Mice that express a human CD19 transgene (hCD19TG) 
have been previously generated to determine whether 
overexpression of CD19 would provide a direct readout of 
biological consequences of augmented receptor function 
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Figure 1. Targeted Disruption of the CD19 
Gene 
(A) Wild-type allele. Intron-exon organization 
oftheCD19gene containing 15exons. Shaded 
squares indicate translated exons and closed 
squares indicate untranslated regions. Do- 
mains are indicated as follows: leader (L), Ig- 
like domains (Igl, lg2), transmembrane do- 
main (TM), cytoplasmic domains, and 3 
untranslated region (321T). 
(B) Structure of the CD19 targeting vector. 
(C) Structure of the predicted targeted allele. 
Gene targeting in ES cells by homologous re- 
combination resulted in acquisition of new 
BamHl and Xbal sites as indicated. 
(0) Southern blot analysis of cells from CDlQ+/ 
+, CDlQ+/-, and CDlQ-I- littermate mice di- 
gested with BamHl and hybridized with the 5’ 
probe indicated in (C). 
(E) lmmunohistochemical analysis of CDlQex- 
pression. Spleen of wild-type and CD19 
deficient littermates. compared with spleen of 
a hCD1QTG mouse, stained with an affinity- 
purified rabbit antiserum against mouse CDlQ. 
hCDlSTG+/+ 
(Zhou et al., 1994). The hCD19TG product is B lineage 
specific in expression and is capable of signal transduction 
in mouse cells. Surprisingly, the development of immature 
and mature B cells in the bone marrow of hCDlSTG+/+ 
mice was significantly impaired depending on the overall 
levelsof CD19expressed(Zhou et al., 1994). Although these 
results demonstrate that expression of the hCD19TG re- 
sults in severe alterations in the early stages of normal B 
cell development, it was not possible to determine whether 
the phenotype of the hCDl9TG mice resulted from human 
CDlSfunctioning asadominant-negative mutation orfrom 
overall augmented CD19 expression with concomitant 
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Figure 2. Lymphocytes Present in Lymphoid Tissues of CDIS 
Deficient Mice 
(A) Bone marrow. 
(B) Blood. 
(C) Spleen. 
(0) Peritoneum. 
Single cell suspensions of leukocytes were isolated from a CD19+/+, 
CD19+/-, and CD19-I- littermate and examined by two-color immu- 
nofluorescence staining with flow cytometry analysis. Cells (6 x lp) 
with the forward and side light scatter properties of lymphocytes were 
analyzed for each sample. Quadrants delineated by squares indicate 
negative and positive populations of cells as determined using unreac- 
tive MAbs as controls. Values represent the percentage of the total 
gated lymphoid cell population that falls into the indicated quadrants. 
All cells were from Pmonth-old mice. These results are representative 
of those obtained with at least 10 mice of each genotype. 
augmented signaling. We have, therefore, extended these 
studies to elucidate the function of CD19 in vivo by gener- 
ating CD19-deficient mice. In contrast with hCD19TG 
mice, CD19-deficient mice manifest significant defects 
during the later stages of B cell maturation and differentia- 
tion. The phenotype of the CDiS-deficient mice, in combi- 
nation with results generated with hCD19TG mice that 
overexpress CDl9, demonstrate that CD19 is a regulator 
of cell surface receptor signaling that modulates signaling 
thresholds for both early negative selection and later 
clonal expansion of the peripheral B cell pool. 
Results 
Generation of COW-Deficient Mice 
CDlS-deficient mice were generated by mutation of the 
CD19 gene in embryonic stem (ES) cells using homolo- 
gous recombination. The exon encoding the transmem- 
brane domain and 7 of 9 exons that encode cytoplasmic 
domains were replaced with a neomycin resistance 
marker that terminates translation (Figures lA, lB, 1C). 
Following transformation, two ES cell clones out of 158 
screened had the predicted mutation as determined by 
Southern blot analysis of restriction endonuclease-digested 
genomic DNA. One ES cell clone generated chimeric 
mice, which transmitted the mutation 10 their progeny(Fig- 
ure ID). Mice heterozygous for the targeted allele were 
mated and CD19+/- and CD19-/- mice were obtained 
at the expected Mendelian frequency. CD1 9-/- mice were 
deficient in CD19 expression as determined by immuno- 
histochemical analysis of spleen using a polyclonal antise- 
rum reactive with CD19 (Figure 1E). CDlS-deficient mice 
thrived and reproduced as well as their wild-type lit- 
termates and did not present any obvious abnormalities 
during the first 4 months of life. 
B Cell Development in CDlQDetlcient Mice 
Deletion of CD19 from the cell surface had no major delete- 
rious effects on the generation of 6 cell precursors in the 
bone marrow as near normal numbers of immunoglobulin 
M- (IgM-) B220+ pro-B and pm-8 cells, IgM+ 8220’” im- 
mature B cells or IgM+ B220M mature B cells were ob- 
served (Figure 2A; Table 1). Similarly, the frequencies of 
CD43+, HSA+, and 8C3/BP-1’ early B cell precursors were 
not significantly different from those of wild-type lit- 
termates. On average, the number of IgM+ B220+ B cells 
in blood was similar in wild-type and CD19-I- littermates 
Table 1. Frequency of El Lymphocytes from CDlSDeficient and hCDl9 Transgenic Mi& 
Mouse 
. . . 
Bone Marrow Blood Spleen Peritoneum 
B220+ 8220” 8220”’ IgM’ B Cell IgM+ B Cell IgM+ 
IgM- IgM’ lgM+ 8220’ (x Number lO*/ml) 8220’ (x Number IO+‘) 8220’ 
Wild-type littermate 44 It 11 15 f 4 6*2 40 f 5 1.5 f 0.5 43*9 40 * 6 49 * 10 
CD19+‘- 36 f 10 14 f 4 11 f 6 41 f 13 1.5 f 0.7 36*12 36*:8 45 f 12 
CDl9-‘- 39 * 7 14 i 6 9*4 37 f 12 1.5 f 1.2 27 f 7< 16 i 4c 13 f 75 
Wild-type littermate 23 k 5 11 * 4 16 f 3 61 f 13 3.6 f 1.9 56 zt 7 76 f 7 37 * 11 
hCDlgTG+‘- 27 f 3 9*2 7 f 3’ 24 f 6’ 0.6 f 0.6O 40 * 3” 50 * 21’ 30*9 
hCDlSTG+‘+ 21 f 6 5 f 2D 3 * 15 9 f 40 0.2 f O.lC 22 f 4e 14 f 2c 11 f 4c 
a Values ( f SD) represent results obtained from 6-14 different mice. Numbem represent the percentage of lymphocytes (based on side and 
forward light scatter properties) expressing the indicated cell surface markers as determined in Figure 2 using two-color immunofluorescence 
staining. The background percentage of cells that were positive (<I%) was subtracted from the values shown. Mice were -2 months old. B cell 
numbers were calculated based the volume of blood or the total number of spleen cells. 
b The percentage of cells was significantly less than in control littermates, p < 0.05; c p < 0.01; as determined using the StudenYs t test. 
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Figure 3. B Lymphocytes Present in the Peritoneal Cavity of CD19 
Deficient Mice 
Peritoneal leukocytes were isolated from CD19+/+ and CD19-I- lit- 
termates by lavage and examined by two-color immunofluorescence 
staining with flow cytometry analysis. Cells (6 x l(r) with the forward 
and side light scatter properties of lymphocytes were analyzed for 
each sample. Quadrants delineated by squares indicate negative and 
positive populations of cells as determined using unreactive MAbs 
as controls. All cells were from P-month-old mice. These results are 
representative of thoseobtained, with at least 6 mice of each genotype. 
(Table 1). However, some variability in numbers was ob- 
sewed in some CD19+/- and CD19-/- mice in compari- 
son with wild-type littermates (Figure 28). In contrast, there 
was a consistent and significant reduction in the number 
of B cells found in the spleen (55% reduction, p < 0.006; 
figure 2C; Table 1) and peripheral lymph nodes of 
CD19-I- mice, although heterozygous mice were similar 
to their wild-type littermates on average (Table 1). Despite 
the marked differences in total B cell numbers and fre- 
quency of B cells, no significant differences in IgD, CD5, 
CD1 8, CD21, CD23, CD43 CD44, HSA, or syndecan ex- 
pression were observed on blood or spleen B cells when 
large numbers of CDlS-deficient mice were compared 
with their wild-type littermates. Although some variability 
in intensities of expression and frequency of antigen- 
positive B cells were observed with CDlS-deficient mice 
as shown for the levels of 8220 expression in Figures 
28 2C, these differences were not consistent and varied 
between individual CDlS-deficient mice. There were also 
no detectable differences in the size (light scatter proper- 
ties) of CD19-/- B lymphocytes isolated from bone mar- 
row, blood, or spleen when compared with wild-type lit- 
termates. Histologic examination of the spleen and lymph 
nodes from CDlO-deficient mice and their wild-type lit- 
termates did not reveal detectable alterations in morphol- 
ogy and normal numbers of primary follicles were present 
(see Figure 1 E). There were no detectable changes in the 
development or number of CD3+ T lymphocytes or myelo- 
monocytic cells in any of the tissues examined. Therefore, 
despite the early appearance of CD19 in B cell develop- 
ment, these results indicate that expression of CD19 is 
required during the later stages of B cell maturation where 
it may regulate clonal expansion or maintenance of the 
peripheral B cell pool. 
Decreased Peritoneal B Cells In 
CD194eflclent Mice 
Surprisingly, there was a dramatic reduction (74%, p < 
0.001) in the frequency of IgM+ 8220’ B cells observed in 
the peritoneal cavity of homozygous CD19deficient mice 
(seeFigure 2D; Table 1). Heterozygous CD19+/- mice 
were similar to wild-type littermates (Table 1). A unique 
feature of peritoneal B cells is the presence of the Bl 
subpopulation, which was initially identified by the expres- 
sion of CD5 (Kantor, 1991). However, other phenotypic 
characteristics also differentiate these cells from conven- 
tional (82) B cells. Bl cells express high levels of IgM, 
low to negligible levels of IgD, low levels of 8220, and 
lack CD23 (Hardy et al., 1994; Waldschmidt et al., 1991). 
Phenotypic analysis of the peritoneal B cells from CD19- 
deficient mice showed that the number of cells with the 
phenotypic characteristics of Bl B cells was dramatically 
reduced (Figure 3). B cells found in the peritoneum of 
CDlS-deficient mice predominantly and consistently ex- 
pressed high levels of IgM, IgD, and 8220. Although the 
overall frequency of CD5+ B cells was also reduced (Figure 
3) the proportion of these cells among IgM+ B cells was 
not significantly altered (CD1 9+/+ mice, 31% f 16%; 
CD19-/- mice, 27% f 21%, n = 5). The proportion of 
CD23+cells among IgM’ B cells was not significantlydiffer- 
ent between CD19+/+ mice (19% *110/b, n = 5) and 
CD19-/- mice (10% *7%). The dramatic decrease in 
numbers of peritoneal B cells with many of the characteris- 
tics of Bl B cells may indicate that CD19 expression is 
required for the self-renewal capacity of this subset of B 
cells. 
B Cell Development In #Ice that Overexpress CD19 
In contrast with CD1 g-deficient mice, early B cell develop- 
ment in hCDl9TG+/+ mice is significantly impaired (Zhou 
et al., 1994). In this study, one transgenic mouse line (hi 9- 
1) that expresses 2- to 3-fold higher levels of CD19 (Zhou 
et al., 1994) was examined. In hCD19TG mice housed 
under the same conditions as the CDlSdeficient mice the 
frequency of IgM- B220+ pro-B ,and pre-B cells in the bone 
marrow was not affected by increased CD1 9 expression 
(Table 1). However, the frequency of IgM+ 8220” immature 
B cells in the bone marrow was reduced by 55% (p = 
O.OOS), with IgM+ B220hi B cell numbers reduced by 81% 
(p < 0.001) (Table 1). Homozygous hCD19TG mice also 
had reduced numbers of blood (95% decrease), splenic 
(82%) and peritoneal (70%) B cells (Table 1). Consistent 
with earlier observations that the effect of the hCDl9TG 
was dependent on the levels of CD19 expression, the ef- 
fects were less dramatic in heterozygous hCD19TG mice 
(Table 1). Therefore, the phenotypic effects of overex- 
pressing CD1 9 differed markedly from those resulting from 
not expressing the receptor. 
$lQ-Deficient Mice 
Figure 4. Proliferation of CDlS-Deficient B Cells in Response to Mito- 
genie Signals 
Spleen B cells (1 x 105/well) from CDIQ-I- mice and wild-type lit- 
termates were purified by complement-mediated lysis of T cells. I3 
cells were cultured for 72 hr with the indicated amounts of (A) LPS. 
or(B) anti-IgM antibodies, or were cultured with (C) anti-IgM antibodies 
(5 &ml) plus the indicated concentrations of 11-4. Proliferation was 
assessed by the incorporation of labeled thymidine (1 pCi/well) added 
during the last 12 hr of culture. Values represent the mean values (f 
SD) obtained from triplicate cultures. These results are representative 
of those obtained in four to ten independent experiments. 
I3 Cell Proliferation in Mice that Lack 
or Overexpress CD19 
Since CD19 has been proposed as a signal transduction 
molecule important for B cell activation, the effect of CD1 9 
loss and overexpression on B cell proliferation was exam- 
ined. The capacity of purified B cells from CDl9-deficient 
mice to proliferate in response to lipoloysaccharide (LPS) 
was consistently lower over a range of mitogen concentra- 
tions (0.1 vglml, 67% f 29% lower, p < 0.005, 10 experi- 
ments; 1 .O wg/ml, 66% -c 26%, p < 0.005; 10 @ml, 71% 
f 22%, p < 0.005) when compared with wild type lit- 
termates (Figure 4A). Activation of B cells with increased 
concentrations of LPS (40 pglml) did not correct the defi- 
ciency in proliferation. The proliferative response of B cells 
from CD19-deficient mice to antibody cross-linking of sur- 
face IgM was also consistently lower (54% -c 20% at 10 
pg/ml, four experiments) (Figure 48). Similar results were 
obtained when the B cells were activated using submito- 
genie concentrations of anti-IgM antibodies with increas- 
ing concentrations of IL-4 added to the cultures (Figure 
4C). Proliferation of 6 cells from CD1 9+/- mice was similar 
to that observed with wild type littermates. Although back- 
ground levels of proliferation observed in media alone 
were not significantly different between CDlO-deficient 
and wild-type B cells, proliferation of CD1 9-/- B cells was 
consistently lower at all mitogen concentrations examined. 
An equally dramatic effect on mitogenic responses re- 
sulted from overexpression of CD19. However, the prolif- 
eration of purified B cells in response to a range of LPS 
concentrations (0.1-10 &ml) was augmented in hCD19TG 
mice (Figure 56). In three experiments, the mean values 
of proliferation obtained for B cells from hCD19TG mice 
were increased when compared with wild-type littermates 
by the following: 0.1 pg/ml LPS, 545%, p < 0.05; 1 .O pgl 
ml LPS, 396%, p < 0.03; 10 pglml LPS, 290%, p < 0.02. 
Heterozygous hCD19TG mice had intermediate levels of 
augmented proliferation consistent with a gene dosage 
effect. A consistent observation was that unstimulated B 
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Figure 5. Proliferation of CD1 g-Deficient and hCD19TG B Cells in Re- 
sponsa to LPS 
Spleen B cells (1 x W/well) from CD19-I- mice and wild-type lit- 
termates (A) or from hCDlgTG+/+ mice and wild-type littermates (B) 
were purified and cultured as in Figure 4. Values represent the mean 
values ( f SD) obtained from triplicate cultures. These results are 
representative of those obtained in (A) ten or (B) three independent 
experiments. 
cells from hCD19TG mice had higher background levels 
of spontaneous proliferation than wild-type littermates with 
a 5.2- -c 2.5-fold (n = 4, p < 0.02) increase (Figure 56). 
Similar results were obtained with cross-linking surface 
IgM (10 pglml). Purified B cells from hCD19TG+/+ mice 
also survived longer in culture without mitogen stimulation 
than B cells from control litermates (data not shown). 
These results confirm that overexpression of the hCDl9TG 
does not exet? toxic or nonspecific inhibitory effects on B 
cell function and demonstrate that expression of CD19 
augments B cell responses to a variety of transmembrane 
signals. 
Serum lmmunoglobulin Levels in Ylce that Lack 
or Overexpress CD19 
Since 6 cell proliferation was impaired in CD1 g-deficient 
mice, serum immunoglobulin levels in unimmunized mice 
were determined to assess the influence of this deficiency 
on B cell differentiation. The serum levels of all immuno- 
globulin isotypes examined were significantly reduced in 
CD19-deficient mice when compared with wild-type lit- 
termates (Figure 6A). On average, IgM levels were signifi- 
cantly reduced by 75%, IgGl by 66%, IgGPa by 64%, 
IgG2b by 72%, lgG3 by 57%, and IgA by 46% (Table 2). 
Thus, the combination of decreased B cell numbers along 
with the decreased proliferative responses of CD19- 
deficient mice had a considerable impact on the immune 
status of these mice. 
The influence of CD19 deficiency on the humoral im- 
mune response was assessed by immunizing mice with 
a T cell-dependent antigen, 2,4dinitrophenol-conjugated 
keyhole limpet hemocyanin (DNP-KLH). CDlO-deficient 
mice mounted modest primary IgM and IgGl responses 
(<lo% on average) following immunization when com- 
pared with wild-type littermates (Figure 7). Although the 
secondary humoral response following rechallenge was 
more substantial, IgM and IgGl responses were generally 
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Figure 6. Serum lmmunoglobulin Levels of CDlQDeficient Mice and 
hCD19TG Mice 
lmmunoglobulin levels of P-month-old mice were determined by iso- 
type-specific ELISA. 
<300/o of those observed in wild-type littermates. There- 
fore, B cells can differentiate into plasma cells in the ab- 
sence of CD19, although at a significantly reduced rate. 
In contrast with the resultsobtained with CDlS-deficient 
mice, hCD19TG mice had an overall increase in serum 
immunoglobulin levels (see Figure 66) despite dramatic 
reductions in the number of peripheral B cells (see Table 
1). On average, IgM levels were increased by 20%, lgG2a 
by 84%, and lgG2b by 168% (see Table 2). By contrast, 
IgGl levels were reduced by 39%, lgG3 by 77%, while 
IgA levels were not significantly changed. Thus, overex- 
pression of CD19 appears to render B cells more suscepti- 
ble to differentiation induction, yet significantly skews the 
response manifest as different immunoglobulin isotypes. 
Discussion 
B Cell Development in Mice that Lack 
or Overexpress CD19 
CD19 is one of the earliest cell surface molecules ex- 
pressed by human B lineage cells during development, 
which persists throughout differentiation. Although CD19 
expression in mice has only been examined at the mRNA 
level, it is likely to be expressed broadly during B cell devel- 
opment, since it is expressed by cell lines representative 
of pro-B and pre-B cells, as well as mature B cells (Zhou 
et al., 1991). Expression of the hCD19TG in mice is also 
B cell-restricted, and its expression appears during early 
pro-B cell development and persists throughout matura- 
tion (Zhou et al., 1994). Surprisingly, despite its early ap- 
pearance during ontogeny, deletion of CD19 did not have 
a significant effect on early B cell development in the bone 
marrow (Figure 2; Table 1). Therefore, although CD19 may 
have functional activities during this stage of development, 
its function is not a requirement for the normal generation 
and maturation of bone marrow B cells. In contrast, there 
(A) Serum immunoglobulin levels of paired CD19+/+ (closed circles) 
and CD19-I- (open circles) littermates are shown. Results are repre- 
sentative of those obtained with thirteen CDlSdeficient mice and four- 
teen wild-type mice are shown in Table 2. 
(B) Serum immunoglobulin levels of paired wild-type (WT, closed cir- 
cles) and hCD19TG (open circles) mice are shown. 
Table 2. Serum lmmunoglobulin Levels of CDlQDeficient and hCD19 Transgenic Mice’ 
Mean Serum lmmunoglobulin Values ( f SD, pg/ml) 
CDlS-Deficient I&c@ hCD19 Transgenic Mice” 
lmmunoglobulin lsotype Control littermate CD19 .‘~ Control littermate hCDl9TG’” 
IgM 744 f 443 163 f 124 911 f 655 1,092 f 511 
IgG, 669 f 613 94 f 42’ 1,609 2 334 1,101 f 768 
IgGn. 962 f 762 160 f 1120 266 rt 106 490 f 227 
IgGm 752 f 529 213 f 140’ 1,426 f 152 3,634 f 2,5W 
I$% 169 f 102 61 f 36’ 201 f 96 46 f 246 
IeA 111 f 54 56 f 12’ 72 2 19 66*5 
’ lmmunoglobulin levels of P-month-old mice were determined by isotypeapecific ELISA. 
’ Mean serum immunoglobulin levels of thirteen paired CD19+‘+ and fourteen CD19” littermates were determined as shown in Figure 6A. 
c Mean serum immunoglobulin levels of seven hCD19TG and seven wild-type mice are as shown in Figure 68. 
d lmmunoglobulin levels were significantly different from control littermates, p < 0.05; * p < 0.001; as determined using the paired Students t test. 
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Figure 7. Humoral Immune Response of CDlQDeficient Mice to Im- 
munization with a T Cell-Dependent Antigen 
CD19-/- (closed circles) and wild-type P-monthold littermates (open 
circles) were injected intraperitoneally with 100 ug of DNP-KLH in 
complete Freund’s adjuvant on days 0 and 23 (arrows), and bled at the 
indicated times. Levels of anti-DNP-bovine serum albumin antibodies 
were determined using an isotype-specific ELBA for DNP. All results 
are presented as means of triplicate values for individual mice. 
was a significant decrease in the number of peripheral 
B cells in CDlQdeficient mice (Figure 2; Table 1). This 
suggests that positive signals generated through CD19 
during later stages of 6 cell maturation are necessary for 
clonal expansion and maintenance of the peripheral 6 lym- 
phocyte population. 
The decrease in number of peripheral B cells observed 
in CDlSdeficient mice was particularly dramatic in the 
case of peritoneal B ceils (Figures 2D and 3). B-l lineage 
B cells, also referred to as the CD5+, sister or Ly-1 subset, 
are the predominant B lymphocyte subpopulation found 
in the peritoneal cavity of adult mice (Hardy el al., 1994; 
Haughton et al., 1993; Kantor, 1991). One of the most 
distinctive features of the B-l B cell subset is its associa- 
tion with certain types of autoantibodies. However, B cells 
with the phenotypic characteristics of Bl lineage cells 
(IghP, IgDb and 8220’9 were generally absent from the 
peritoneum of CDlgdeficient mice, although the relative 
proportion of CD5+ B cells among IgM+ B cells was not 
significantly altered (Figure 3). It has been proposed that 
the B-l cell lineage in the adult mouse is the remnant 
of a distinct fetal B cell differentiation pathway, which is 
maintained by the presence of natural antigens without a 
requirement for T cell help (Kantor, 1991). Alternatively, 
B-l cells may represent B cells that have been selected 
by T cell-independent antigens (Haughton et al., 1993). 
Regardless, since the autoantibodies generated by this 
subpopulation of B cells are generally of low affinity, trans- 
membrane signals generated by autoantigens or T cell- 
independent antigens may be insufficient to maintain the 
population during adult life in the absence of signalsgener- 
ated through coreceptor molecules. Thereby, the dramatic 
paucity of B-l B cells in CDl9deficient mice could be 
explained by CD19 functioning as a necessary coreceptor 
in addition to surface immunoglobulin. Thus, CD19 ligation 
on mature B cells may generate signals that result in aug- 
mented proliferative responses to weak or self-antigens 
and ultimately to clonal expansion and maintenance of 
peripheral B cells that express low affinity antigen receptors. 
The phenotype of CDlSdeficient mice was strikingly 
different from that previously obsenred in hCDl9TG mice 
that overexpress CD19 (Zhou et al., 1994). These results 
suggest that quanfitative differences in signaling though 
CD19 can have dramatic effects on B cell development 
depending on the stage of B cell maturation or level of 
signaling through the antigen receptor complex. Although 
both mice have deficiencies in peripheral B cell numbers 
(Table 1), thedeficiency in hCDl9TG mice is likely to result 
from a severe decrease in the generation of nascent B 
cells from the bone marrow. In fact, the hyperresponsive 
nature of B cells from hCDl9TG mice (Figure 5) is likely 
to result in increased clonal expansion of mature B cells, 
which partially repopulate peripheral lymphoid tissues. 
This may, in part, explain why blood B cell numbers are 
reduced by 95%, while spleen and peritoneal B cell num- 
bers were only reduced by 81% and 70%, respectively. 
That the phenotypic alterations obsenred in hCDl9TG 
mice result from altered signaling through CD19 is also 
supported by the finding that the phenotype of heterozy- 
gous hCDl9TG mice is less significantly skewed. 
Prollferative Responses In Mice that Lack 
or Overexprese CD19 
It has been proposed that coligation of CD19 with mem- 
brane immunoglobulin lowers the threshold required for 
signaling through the antigen receptor, thereby promoting 
more effective immune responses (Carter and Fearon, 
1992). Since B lymphocyte antigen receptors are generally 
of low avidity prior to clonal selection and affinity matura- 
tion, this hypothesis has important implications for B cell 
tolerance induction during B cell development and later 
activation in response to antigenic stimulation (Tedder el 
al., 1994). The results of this in vivo study support and 
extend this hypothesis. In particular, the finding that B cells 
from CDlSdeficient mice had a significantly decreased 
capacity to proliferate in response to B cell mitogens and 
cytokines (Figure 4), whereas B cells from mice that over- 
express CD1 9 had an augmented capacity to proliferate 
(Figure 5) clearly implicates CD19 expression as a direct 
regulator of B cell function in vivo. Interestingly, B cells 
from hCDl9TG mice also had higher levels of spontane- 
ous background proliferation, even in the absence of mite- 
genie stimuli. Therefore, CD1 O-mediated signals may play 
a global role in the modulation of B cell responses to a 
variety of signals. It is also important to note that B cells 
that lacked CD1 9 were still able to mount a proliferative 
response, albeit at diminished levels. Therefore, CD1 9 sig- 
naling is not required for proliferation, but is a cell surface 
molecule that can heighten the proliferative potential of 
cells that express it. Nonetheless, these results clearly 
show the importance of CD19 in the regulation of B cell 
activation and suggest that CD19 functions as a central 
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signaling element that may be linked, via tyrosine phos- 
phorylation, to multiple cell surface receptors and signal- 
ing pathways. 
Another important aspect of this study is that the relative 
levels of CD1 9 expressed on the cell surface had marked 
effects on the proliferative capacity of the B cells that ex- 
pressed it. In this regard, the increase in proliferative ca- 
pacity of B cells from heterozygous hCD19TG mice was 
half that of 6 cells from homozygous hCD19TG mice. Simi- 
lar results were obtained with additional lines of hCDl9TG 
mice that express cell surface CD19 over a range of con- 
centrations (P. E. and T. F. T., unpublished data). There- 
fore, small changes in the overall levels of CD19 ex- 
pressed by different B cells as they progress through 
different stages of maturation may have a considerable 
impact on their functional responses (Wolf et al., 1993). 
This may be a particularly important factor for the prolifera- 
tive capacity of human B cell malignancies that universally 
express CD19. Although large variances in CD19 expres- 
sion among malignancies have not been described, there 
is considerable heterogeneity in levels of expression ob- 
served, which are suggested to be physiologically signifi- 
cant by this study. Therefore, a more quantitative analysis 
of the relative levels of CD19 expression in a variety of 
human diseases and malignancies affecting B cell func- 
tion is warranted. 
B Cell Dlfferentlatlon in Mice that Lack 
or Overexpreee CD1 9 
In concordance with an impaired capacity to respond to 
mitogenic signals, CDlg-deficient mice had an overall 
77% reduction in serum immunoglobulin levels when com- 
pared with wild-type littermates (Figure 6A) and a similarly 
reduced humoral immune response to immunization with 
a T cell-dependent antigen (Figure 7). While serum levels 
of all immunoglobulin isotypes were lower in the CD19- 
deficient mice, substantial decreases occurred in IgGl 
and lgG2a levels, which were only 14%-l 6% of the values 
found on normal littermates. Therefore, it does not appear 
that the reduction in serum immunoglobulin levels results 
solely from a decrease in the number of peripheral B cells, 
but rather results from alterations in the frequency of B 
cells that differentiate. The exaggerated losses of both 
IgGl and lgG2a do not correlate directly with the loss of 
a particular known B cell function or cytokine response, 
but clearly suggest that Tcell-B cell interactions that foster 
these isotype responses may be particularly affected by 
loss of CD19. In view of the critical role that the B cell 
activating agent plays in determining the effects that indi- 
vidual lymphokines have on immunoglobulin production 
and on isotype selection (Snapper and Mond, 1993), it is 
not surprising that the alterations in susceptibility to trans- 
membrane signals manifest in CD19-deficient mice skew 
the humoral immune response. It would be expected from 
these results that loss of CD19 would also lead to a de- 
crease in secondary follicle and germinal center formation 
in lymphoid tissues following antigen challenge. 
A role for CD19 in B cell differentiation is reinforced by 
the finding that serum immunoglobulin levels in hCDl9TG 
mice that overexpress CD19 were -40% higher than in 
wild-type littermates (Figure 6B). This increase is in spite 
of a >60% decrease in the number of peripheral B cells. 
Therefore, the augmented proliferative capacity exhibited 
by B cells that overexpress CD19 is further manifest as 
an augmented differentiative capacity. However, a unique 
feature observed in hCDl9TG mice was that serum lgG2b 
levels were selectively increased 166% compared with 
control littermates, while lgG3 levels were reduced by 
77%. A molecular basis for the paired skewing of these 
two particular immunoglobulin &types has not been pre- 
viously described. However, since lgG2 isotypes predomi- 
nate during T cell-dependent antibody responses, while 
the generation of lgG3 principally results from T cell-inde- 
pendent antibody responses, overexpression of CD1 9 
could augment and/or replace signals generated through 
T cell-independent antigens and shift the immune re- 
sponse to a more T cell-dependent phenotype. Alterna- 
tively, the hyperresponsive phenotype of B cells that over- 
express CD19 may extent to cytokine receptors, such that 
B cell responses to the cytokines that influence isotype 
switching are exaggerated. Extensive studies examining 
the humoral response to well-characterized T cell-depen- 
dent and T cell-independent antigens will be required to 
dissect these apparently complex phenotypes further. 
Nonetheless, these results strongly indicate that CD19 
plays an essential role in the generation of humoral im- 
mune responses, a finding that has not been predicted 
from previous in vitro studies of CD19 function. 
The Phenotype of CD19-Deficient Mice Is Unique 
The phenotype of the CD1 g-deficient mice is quite distinct 
from that of other mice rendered deficient in immunologi- 
cally relevant cell surface receptors (Pfeffer and Mak, 
1994). Reduced levels of serum immunoglobulins have 
been reported in mice deficient in the CD40, CD40-ligand, 
and CD26 surface proteins that are involved in interactions 
between B and T cells, although these mice also have 
nearly normal numbers of peripheral B cells (Kawabe et 
al., 1994; Renshaw et al., 1994; Shahinian et al., 1993). 
However, CD26deficient mice have reduced levels of 
IgGl and lgG2b, but elevated levels of lgG2a. CD40 and 
CD40-ligand-deficient mice also have decreased levels 
of serum immunoglobulins, but have higher levels of IgM 
and lgG3 (Kawabe et al., 1994; Renshaw et al., 1994). In 
further contrast with CDlSdeficient B cells, CD40- and 
CD40-Iigand-deficient mice are normal in their capacity 
to respond to B cell mitogens (Kawabe et al., 1994; Ren- 
shaw et al., 1994) and generate heightened IgM responses 
to T cell-dependent antigens with no IgGl response (Ka- 
wabe et al., 1994). Mice that lack MHC class II antigens 
have normal numbers of B cells, which can differentiate 
into plasma cells, but there are several aberrations in the B 
cell compartment (Gosgrove et al., 1991). Although serum 
IgGl levels and T cell-dependent responses are de- 
creased, these mice also have significant deficiencies in 
T cell development that may contribute to this phenotype. 
B cells from CD45 exon 6-deficient mice are similar to B 
cells from CD1 9-deficient mice in that they have defective 
proliferative responses following cross-linking of surface 
immunoglobulin (Kishihara et al., 1993). However, CD45 
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exon Gdeficient mice respond normally to LPS stimula- 
tion and have normal immunoglobulin levels, in contrast 
with CDlSdeficient mice. While U-deficient mice share 
phenotypic similarities with hCDl9TG mice (Kitamura et 
al., 1992; Zhou et al., 1994) the phenotype of CDl9- 
deficient mice is quite distinct. Therefore, it is likely that 
CD19 mediates cellular functions distinct from those de- 
scribed for other currently characterized cell surface re- 
ceptors. 
Role for CD19 In Negative Selection 
of Bone Marrow B Cells 
Prior to leaving the bone marrow, immunological tolerance 
to self-antigens is achieved in part by the clonal deletion 
of immature 6 cells that express high affinity IgM receptors 
that are reactive with self-antigens (Goodnow, 1992; Hart- 
ley et al., 1993; Nemazee and Biirki, 1989). B cells are 
not rendered tolerant if the antigen concentration is low 
or the inherent affinity of the antigen for the lymphocyte 
receptor is low (Adelstein et al., 1991). However, little is \ 
known about the extent to which negative selection cen- 
sors B cells that bind to autoantigens through low affinity 
receptors, since the elimination process must exhibit a 
lower aff inity limit, which prevents too large a fraction of the 
B cell repertoire from being purged (Hartley and Goodnow, 
1994). What is apparent is that selection depends on the 
existence of triggering thresholds for intracellular signals 
that are influenced by antigen valency and concentration, 
together with receptor affinity (Goodnow, 1992; Nemazee 
et al., 1991). The finding that overexpression of CD19 re- 
sults in increased sensitivity to transmembrane signals in 
combination with the finding that overexpression of CD19 
results in clonal elimination of B cells in the bone marrow 
suggests that CD19 regulates antigen-dependent nega- 
tive selection of immature B cells during maturation in 
the bone marrow. Since impaired B cell development in 
hCDl9TG mice is directly correlated with the number of 
cell surface hCDl9 molecules expressed (Zhou et al., 
1994) increased receptor number may translate into the 
overproduction of intracellular signals, which exceeds the 
signaling threshold and results in down-regulation of im- 
mature B cell development (Table I). Since many preim- 
mune B cells produce self-reactive antibodies (Kearney 
et al., 1992; Striebich et al., 1990) lowering the surface 
immunoglobulin signaling threshold for negative selection 
by overexpressing CD19 may explain the severe defi- 
ciency of B cells in hCDl9TG mice. Consistent with this 
hypothesis, bone marrow 6 cell development in transgenic 
mice that express rearranged heavy and light chain genes 
specific for hen egg lysozyme (Hartley et al., 1991) is not 
inhibited by overexpression of CD19 (data not shown). 
Thus, overexpression of CD1 9 may augment transmem- 
brane signals generated through low affinity antigen re- 
ceptors, thereby leading to increased clonal deletion of 
immature B cells in the bone marrow. 
There are many striking functional parallels between 
CD19 and the CD4 and CD8 accessory molecules that 
modulate low affinity interactions between T cell receptors 
and autoantigens during thymocyte selection and aug- 
ment mature T cell proliferative responses to processed 
antigen (Lee et al., 1992; Loh, 1991; Robey et al., 1992; 
Weiss and Littman, 1994). CD4 and CD8 compensate for 
a low affinity of the T cell antigen receptor for its antigen 
and for the low number of such complexes that may be 
present on an individual antigen-presenting cell. Thus, 
CD19 may serve an analogous accessory function in- 
volved in modulating early B cell development, which simi- 
larly continues to serve a costimulatory role in the function 
of mature B lymphocytes. As occurs with surface immuno- 
globulin, the outcome of CD19 ligation is therefore mani- 
fest in different ways depending on the differentiation state 
of the 6 cell. The finding that early 6 cell development 
occurs normally in CDl9-deficient mice suggests that 
CD19 function is not required for clonal expansion during 
this stage of differentiation. However, this is consistent 
with the finding that bone marrow development is gener- 
ally antigen independent and that positive selection is un- 
likely to occur in a general sense during early B cell devel- 
opment (Nossal, 1994; von Boehmer, 1994). Nonetheless, 
these experiments provide an in vivo framework for CD1 9 
function and demonstrate that CD19 is likely to be critical 
in defining signaling thresholds for cell surface receptors 
that regulate B lymphocyte selection, activation, and dif- 
ferentiation. 
Experimental Procedures 
Productlon of CDlS-Deflclent Mice 
DNA encoding the mouse CD19 gene was isolated from CA Fi and 
129ISvstrain miceasdescribed(Zhouet al., 1991,1992).The targeting 
vector was constructed into pBluescript KS(+) (Stratagene, La Jolla, 
California) by the sequential insertion of fragments of genomic DNA 
containing the CD19 gene and flanking sequences. The 5’ end of the 
targeting vector was generated from a Bgll-Accl fragment of CA Fl 
strain DNA that contained exons l-4. The 3’end of the targeting vector 
was obtained from a - 5 kb Xbal fragment of 129/Sv strain DNA that 
contained exons 13-15. These DNA fragments flanked the Xhol to 
Sail fragment of DNA from pMCl-neo poly(A) (Stratagene) that con- 
tained the TK promoter and poly(A) signal sequence. The vector was 
linearized using a unique Notl restriction site, which flanked the 3’end 
of the CD19 gene insert. ES cells were transfected with linearized 
plasmid DNA and selected for 6418 resistance as described (Koller 
and Smithies, 1969). Genomic DNA from individual selected clones 
was digested with BamHl and hybridized with a probe external to the 
targeting vector to screen for homologous recombination as described 
(Zhou et al., 1994). A DNA restriction fragment of - 7 kb corresponded 
to the wild-type allele, while a new -4.0 kb fragment resulted from 
the targeted allele. Two clones containing both alleles were identified 
out of 156 G4lEresistant ES colonies screened. The structure of the 
targeted allele was further analyzed by Xbal digestion using the 5’ 
flanking probe. A DNA restriction fragment of - 9.5 kb corresponded 
to the wild-type allele, while a new - 6.5 kb fragment resulted from 
the targeted allele. The Southern blot pattern obtained in all cases 
was consistent with the appropriate predicted mutation, indicating that 
detrimental recombinations did not occur in the vicinity of the desired 
homologous recombination. Two targeted ES cell clones were injected 
into 3.5dayold C57BU6 blastocysts, which were then transferred to 
foster mothers. One clone generated chimeric mice, which transmitted 
the mutation to their progeny (4 of 9). Mice carrying the mutant CD19 
allele were intercrossed and the genotype of the offspring determined 
by Southern blot analysis of DNA obtained from tail biopsies. 
lmmunohlstochemlstry 
Spleens were obtained from littermates and kept in liquid nitrogen 
until use. Gelatin-embedded frozen tissue sections were air dried, and 
subsequently fixed in acetone. The sections were incubated with an 
affinity-purified rabbit antiserum generated against recombinant mouse 
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CD19 cytoplasmic tail protein (provided by Dr. J. Cambier, Denver, 
Colorado) at a predetermined optimal concentration. This antiserum 
reacts with both human and mouse CD19, since the cytoplasmic do- 
mains of both molecules are highly homologous. The sections were 
then treated with biotinylated anti-rabbit immunoglobulin antibodies 
that were preabsorbed with mouse immunoglobulin, washed with sa- 
line, incubated with the ABC-Elite complex (Vector Laboratories, Burt- 
ingame, California) and processed as described (Zhou et al., 1994). 
CD19 expression is visualized as red staining on a background of 
hematoxylin-stained tissue. Control sections stained with the second- 
ary antibody alone generated results identical to those shown for 
CD19deficient mice. 
Flow Cytometry and Antibodies 
Single cell suspensions of mouse leukocytes were isolated from lit- 
termates and examined immediately by two-color immunofluores- 
cence analysis as described (Zhou et al., 1994). Antibodies used in 
this study included the following: fluoresceintonjugated anti-B220 
(CD45RA, RA36B2)MAb(Coffman and Weissman, 1961); biotinylated 
and fluorescein isothiocyanate-conjugated goat anti-mouse IgM iso- 
type-specific antibodies(Southern Biotechnology Associates, Incorpo- 
rated, Birmingham, Alabama); HSA (M1169, Pharmingen, San Diego, 
California); CD43 (S7, Pharmingen); 6C3/BP-1 (6C3, Pharmingen); 
CD5 (537.3, Pharmingen), CD16 (C71/16, Pharmingen), CD23 (8384, 
Pharmingen), Pgp-1 (CD44. Pharmingen); CD21 (7G6, provided by 
Dr. T. Kinoshita, Osaka, Japan); Syndecan-1 (261-2. Pharmingen); 
and lg(5a)7.2 and lg(5b)6.3 (anti-mouse IgD allotypes a and b) (Oi and 
Herzenberg, 1979; Oi et al., 1976). Phycoerythrin-conjugated Strepta- 
vidin (Fisher Scientific, Fair Lawn, New Jersey) was used to reveal 
biotin-coupled antibody staining. Cells were washed and analyzed on 
an Elite flow cytometer (Coulter, Incorporated, Hialeah, Florida). Cells 
(6 x 10’) with the forward and side light scatter properties of lympho- 
cytes were analyzed for each sample with fluorescence intensity 
shown a four decade log scale. Positive and negative populations of 
cells were determined using unreactive mAb as controls for back- 
ground staining. 
B Cell Proliferation 
Spleen B cells were purified by complement-mediated lysis of T cells 
with an anti-T cell receptor MAb H57-597 (provided by Dr. Ft. Kubo, 
Denver, Colorado). B cells were cultured in 0.2 ml of RPM1 1640 me- 
dium (GIBCO BRL, Gaithersberg, Maryland) containing 10% fetal calf 
serum in 96well flat-bottomed plates with LPS (Escherichia coli sero- 
type 011 l:B4, Sigma, St. Louis, Missouri) as indicated for 72 hr. B 
cells were also stimulated with F(ab’b fragments of goat anti-mouse 
IgM antibodies(Cappel Research Products, Westchester, Pennsylva- 
nia) either alone or in the presence of recombinant mouse IL-4 (Gen- 
zyme Corporation, Cambridge, Massachusetts). Proliferation was as- 
sessed by the incorporation of labeled thymidine (1 pCi/well) added 
during the last 12 hr of culture. 
lmmunlzatlon of Mice 
Mice (2 months old) were immunized intraperitoneally with 100 ug of 
DNP-KLH (Calbiochem-Novabiochem Corporation, La Jolla, Califor- 
nia) in complete Freund’s adjuvant at day 0 and were boosted at day 
23. Animals were bled before and 6, 16, and 30 days after the first 
immunization. TNP-specific antibody titers of sera were measured as 
described below. 
Mouse lmmunoglobulln Isotype-Specific ELlSAs 
Enzyme-linked immunosorbent assay (ELISA) plates (Costar, Cam- 
bridge, Massachusetts) were coated with 100 ul of goat anti-mouse 
immunoglobulin antibodies (5 pglml diluted into Tris-buffered saline, 
Southern Biotechnology Associates, Incorporated) at 4OC overnight. 
The plates were washed twice with Tris-buffered saline (TBS), incu- 
bated with 1% bovine serum albumin and 1% gelatin in TBS for 60 
min, and washed again three times with TBS. The test sera were 
diluted 1110,000 in TBS and 100 ul of diluted serum was incubated 
at room temperature for 1.5 hr in triplicate ELISA wells. Each assay 
included the titration of affinity purified mouse IgM, IgGl, IgGPa, 
IgGPb, lgG3, and IgAantibodies (Southern Biotechnology Associates, 
Incorporated), which was used to generate a standard curve. Plates 
were washed three times and further incubated with alkaline phospha- 
tase-conjugated goat anti-mouse isotype-specific antibodies (2 pglml 
in TBS, Southern Biotechnology Associates, Incorporated) for 1 hr at 
room temperature. Finally, afkafine pho@atase substrate (p-nllenyl 
phosphate, Sigma) was added to the plates at 1 m@ml to vtsuafii posC 
tive reactions. The OD of the reaction mixture at 405 nm wavelength 
was quantitated using an ELISA reader. The relative concentration of 
immunoglobulin in individual samples was calculated by comparing 
the mean OD obtained for triplicate wells to a semilog standard curve 
of titrated plasma using linear regression analysis. 
TNP-specific antibody titers of sera were measured as above except 
samples were added to ELISA plates coated with DNP-bovine serum 
albumin (Calbiochem-Novabiochem Corporation). 
StatIstIcal Analysis 
All data are shown as mean values f SD. Analysis of variance (AN- 
OVA) was used to analyze the data and the student’s t test was used to 
determine the level of significance of differences in population means. 
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